Clinical development of Modified Vaccinia virus Ankara vaccines.

Clinical development of Modified Vaccinia virus Ankara vaccines.

Zobrazit další vydání (1)

The smallpox vaccine Vaccinia was successfully used to eradicate smallpox, but although very effective, it was a very reactogenic vaccine and responsible for the deaths of one or two people per million vaccinated. Modified Vaccinia virus Ankara (MVA) is a replication-deficient and attenuated derivat...

Podrobná bibliografie
Hlavní autor:	Gilbert, S
Médium:	Journal article
Jazyk:	English
Vydáno:	2013

Podobné jednotky

Clinical development of Modified Vaccinia virus Ankara vaccines
Autor: Gilbert, S
Vydáno: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
Autor: Olga Vladimirovna Orlova, a další
Vydáno: (2022-09-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
Autor: Gilbert, S, a další
Vydáno: (1999)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
Autor: Moorthy, V, a další
Vydáno: (2003)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
Autor: Kaïdre Bendjama, a další
Vydáno: (2017-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
Autor: Volker Sandig, a další
Vydáno: (2013-11-01)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
Autor: Juan García-Arriaza, a další
Vydáno: (2021-08-01)

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
Autor: Alina Tscherne, a další
Vydáno: (2024-11-01)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
Autor: López-Camacho, C, a další
Vydáno: (2019)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
Autor: Alharbi, N
Vydáno: (2014)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
Autor: César López-Camacho, a další
Vydáno: (2019-11-01)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
Autor: Caroline Staib, a další
Vydáno: (2003-04-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
Autor: Harriet L. Robinson, a další
Vydáno: (2018-09-01)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
Autor: McConkey, S, a další
Vydáno: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
Autor: Rosario, M, a další
Vydáno: (2010)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
Autor: Flavia Chiuppesi, a další
Vydáno: (2024-02-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
Autor: Mingwang Shen, a další
Vydáno: (2024-10-01)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
Autor: Alharbi, N, a další
Vydáno: (2015)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
Autor: C. Staib, a další
Vydáno: (2000-06-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
Autor: Malachy I. Okeke, a další
Vydáno: (2017-10-01)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
Autor: Naif Khalaf Alharbi, a další
Vydáno: (2015-01-01)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
Autor: Moorthy, V, a další
Vydáno: (2003)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
Autor: Moorthy, V, a další
Vydáno: (2003)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
Autor: Schmidt, C, a další
Vydáno: (2008)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
Autor: Behboudi, S, a další
Vydáno: (2004)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
Autor: Schneider, J, a další
Vydáno: (1998)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
Autor: Dorrell, L, a další
Vydáno: (2000)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
Autor: Nereida Jiménez de Oya, a další
Vydáno: (2022-03-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
Autor: Hanke, T, a další
Vydáno: (1998)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
Autor: Cottingham, M, a další
Vydáno: (2008)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
Autor: Maurilia Marcacci, a další
Vydáno: (2020-07-01)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
Autor: Ning Yang, a další
Vydáno: (2022-10-01)

Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
Autor: Winslow, R, a další
Vydáno: (2017)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
Autor: Matthew G Cottingham, a další
Vydáno: (2008-02-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Autor: David A Garber, a další
Vydáno: (2009-01-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
Autor: Goepfert P, a další
Vydáno: (2012-09-01)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
Autor: McConkey, S, a další
Vydáno: (2003)

Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.
Autor: Miriam Nörder, a další
Vydáno: (2010-01-01)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
Autor: Mcshane, H, a další
Vydáno: (2001)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
Autor: Hanke, T, a další
Vydáno: (2007)